Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement

Abstract

Symptoms originating from central nervous system (CNS) are frequently occuring in patients with systemic lupus erythematosus (SLE). Reliable diagnostic markers for this condition are presently lacking. Importantly, CNS involvement in lupus patients is associated with increased morbidity and mortality. The aim of this retrospective evaluate was to study the diagnostic value of cerebrospinal fluid (CSF) cytokine levels in SLE patients with CNS involvement.

34 patients with SLE were hospitalized and investigated for the presence of CNS lupus. These patients were evaluated clinically and with magnetic resonance imaging (MRI) and CSF analyses, as well as with neuropsychiatric tests. 13 patients were found to have CNS lupus whereas another four of the patients fulfilled the criteria for CNS involvement but were excluded from this group due to other causes of CNS involvement. Lastly, in 17 SLE cases, the diagnosis of CNS lupus could not be confirmed.

CSF levels of interleukin-6 (IL-6) and IL-8, as well as the CSF/serum IL-6 ratio, were elevated in the CNS lupus group, compared with the 17 SLE patients not fullfilling a diagnosis of cerebral lupus. Interestingly, follow-up of five patients being successfully treated for CNS lupus revealed profound decrease of intrathecal IL-6 levels. These results indicate that analysis of CSF cytokine levels, especially IL-6 and IL-8, may be useful in the diagnostics and possibly follow-up of SLE patients with cerebral lupus.

Keywords

cytokines SLE CNS autoimmunity brain

Get full access to this article

View all access options for this article.

References

McCune WJ , Golbus J . Neuropsychiatric lupus . Rheum Dis Clin North Am 1988; 14: 149–167 .

Hanly JG , Liang MH . Cognitive disorders in systemic lupus erythematosus. Epidemiologic and clinical issues . Ann NY Acad Sci 1997; 823: 60–68 .

Feinglass EJ , Arnett FC , Dorsch CA et al. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease . Medicine (Baltimore) 1976; 55: 323–339 .

Bresnihan B . CNS lupus . Clin Rheum Dis 1982; 8: 183–195 .

Kaell AT , Shetty M , Lee BC et al. The diversity of neurologic events in systemic lupus erythematosus. Prospective clinical and computed tomographic classification of 82 events in 71 patients . Arch Neurol 1986; 43: 273–276 .

Wong KL , Woo EK , Yu YL et al. Neurological manifestations of systemic lupus erythematosus: a prospective study . Q J Med 1991; 81: 857–870 .

McCune WJ , Golbus J , Zeldes W et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus . New Engl J Med 1988; 318: 1423–1431 .

Boumpas DT , Yamada H , Patronas NJ et al. Pulse cyclophosphamide for severe neuropsychiatric lupus . Q J Med 1991; 81: 975–984 .

McCune WJ , MacGuire A , Aisen A et al. Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning . Arthritis Rheum 1988; 31: 159–166 .

10.

Chinn RJ , Wilkinson ID , Hall-Craggs MA et al. Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus . Arthritis Rheum 1997; 40: 36–46 .

11.

Jarek MJ , West SG , Baker MR et al. Magnetic resonance imaging in systemic lupus erythematosus patients without a history of neuropsychiatric lupus erythematosus . Arthritis Rheum 1994; 37: 1609–1613 .

12.

Abel T , Gladman DD , Urowitz MB . Neuropsychiatric lupus . J Rheumatol 1980; 7: 325–333 .

13.

Sergent JS , Lockshin MD . Editorial: treatment of central nervous system lupus erythematosus .Ann Intern Med 1974; 80: 413–414 .

14.

Ernerudh J , Olsson T , Lindstrom F et al. Cerebrospinal fluid immunoglobulin abnormalities in systemic lupus erythematosus . J Neurol Neurosurg Psychiatry 1985; 48: 807–813 .

15.

Winfield JB , Shaw M , Silverman LM et al. Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction . Am J Med 1983; 74: 837–844 .

16.

Hirohata S , Hirose S , Miyamoto T . Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Their use as estimates of central nervous system disease activity . Arch Intern Med 1985; 145: 1843–1846 .

17.

Hirohata S , Tanimoto K , Ito K . Elevation of cerebrospinal fluid interleukin-6 activity in patients with vasculitides and central nervous system involvement . Clin Immunol Immunopathol 1993; 66: 225–229 .

18.

Yeh TS , Wang CR , Jeng GW et al. The study of anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with systemic lupus erythematosus and central nervous system involvement . Autoimmunity 1994; 18: 169–175 .

19.

Tsai CY , Wu TH , Tsai ST et al. Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections . Scand J Rheumatol 1994; 23: 57–63 .

20.

Alcocer-Varela J , Aleman-Hoey D , Alarcon-Segovia D . Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers . Lupus 1992; 1: 111–117 .

21.

Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter] [see comments] . Arthritis Rheum 1997; 40: 1725-1725 .

22.

Breitbach SA , Alexander RW , Daltroy LH et al. Determinants of cognitive performance in systemic lupus erythematosus . J Clin Exp Neuropsychol 1998; 20: 157–166 .

23.

Helle M , Boeije L , Aarden LA . Functional discrimination between interleukin 6 and interleukin 1 . Eur J Immunol 1988; 18: 1535–1540 .

24.

Aarden LA , De Groot ER , Schaap OL et al. Production of hybridoma growth factor by human monocytes . Eur J Immunol 1987; 17: 1411–1416 .

25.

Tarkowski E , Rosengren L , Blomstrand C et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke . Stroke 1995; 26: 1393–1398 .

26.

Czerkinsky C , Andersson G , Ekre HP et al. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells . J Immunol Methods 1988; 110: 29–36 .

27.

Frei K , Malipiero UV , Leist TP et al. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases . Eur J Immunol 1989; 19: 689–694 .

28.

Houssiau FA , Bukasa K , Sindic CJ et al. Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system . Clin Exp Immunol 1988; 71: 320–323 .

29.

Yan HQ , Banos MA , Herregodts P et al. Expression of interleukin (IL)-1 beta, IL-6 and their respective receptors in the normal rat brain and after injury . Eur J Immunol 1992; 22: 2963–2971 .

30.

Taupin V , Toulmond S , Serrano A et al. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of preand post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand . J Neuroimmunol 1993; 42: 177–185 .

31.

Mathiesen T , Andersson B , Loftenius A et al. Increased interleukin-6 levels in cerebrospinal fluid following subarachnoid hemorrhage . J Neurosurg 1993; 78: 562–567 .

32.

Hirano T . The biology of interleukin-6 . Chem Immunol 1992; 51: 153–180 .

33.

Rothwell NJ , Hopkins SJ . Cytokines and the nervous system II: Actions and mechanisms of action [see comments] . Trends Neurosci 1995; 18: 130–136 .

34.

Giulian D , Lachman LB . Interleukin-1 stimulation of astroglial proliferation after brain injury . Science 1985; 228: 497–499 .

35.

Strieter RM , Kunkel SL , Showell HJ et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta . Science 1989; 243: 1467–1469 .